Sulisobenzone is a potent inhibitor of the global transcription factor Cra

Transcription is carried out by the RNA polymerase and is regulated through a series of interactions with transcription factors. Catabolite activator repressor (Cra), a LacI family transcription factor regulates the virulence gene expression in Enterohaemorrhagic Escherichia coli (EHEC) and thus is a promising drug target for the discovery of antivirulence molecules. Here, we report the crystal structure of the effector molecule binding domain of Cra from E. coli (EcCra) in complex with HEPES molecule. Based on the EcCra-HEPES complex structure, ligand screening was performed that identified sulisobenzone as an potential inhibitor of EcCra. The electrophoretic mobility shift assay (EMSA) and in vitro transcription assay validated the sulisobenzone binding to EcCra. Moreover, the isothermal titration calorimetry (ITC) experiments demonstrated a 40-fold higher binding affinity of sulisobenzone (KD 360 nM) compared to the HEPES molecule. Finally, the sulisobenzone bound EcCra complex crystal structure was determined to elucidate the binding mechanism of sulisobenzone to the effector binding pocket of EcCra. Together, this study suggests that sulisobenzone may be a promising candidate that can be studied and developed as an effective antivirulence agent against EHEC.

Mechanistic and thermodynamic characterization of antiviral inhibitors targeting nucleocapsid N-terminal domain of SARS-CoV-2

The nucleocapsid (N) protein of SARS-CoV-2 plays a pivotal role in encapsulating the viral genome. Developing antiviral treatments for SARS-CoV-2 is imperative due to the diminishing immunity of the available vaccines. This study targets the RNA-binding site located in the N-terminal domain (NTD) of the N-protein to identify the potential antiviral molecules against SARS-CoV-2. A structure-based repurposing approach identified the twelve high-affinity molecules from FDA-approved drugs, natural products, and the LOPAC1280 compound libraries that precisely bind to the RNA binding site within the NTD. The interaction of these potential antiviral agents with the purified NTD protein was thermodynamically characterized using isothermal titration calorimetry (ITC). A fluorescence-based plate assay to assess the RNA binding inhibitory activity of small molecules against the NTD has been employed, and the selected compounds exhibited significant RNA binding inhibition with calculated IC50 values ranging from 8.8 μM to 15.7 μM. Furthermore, the antiviral efficacy of these compounds was evaluated using in vitro cell-based assays targeting the replication of SARS-CoV-2. Remarkably, two compounds, Telmisartan and BMS-189453, displayed potential antiviral activity against SARS-CoV-2, with EC50 values of approximately 1.02 μM and 0.98 μM, and a notable selective index of >98 and > 102, respectively. This study gives valuable insight into developing therapeutic interventions against SARS-CoV-2 by targeting the N-protein, a significant effort given the global public health concern posed due to the virus re-emergence and long COVID-19 disease.

MD simulation and MM/PBSA identifies phytochemicals as bifunctional inhibitors of SARS-CoV-2

The global spread of SARS-CoV-2 has resulted in millions of fatalities worldwide, making it crucial to identify potent antiviral therapeutics to combat this virus. We employed structure-assisted virtual screening to identify phytochemicals that can target the two proteases which are essential for SARS-CoV-2 replication and transcription, the main protease and papain-like protease. Using virtual screening and molecular dynamics, we discovered new phytochemicals with inhibitory activity against the two proteases. Isoginkgetin, kaempferol-3-robinobioside, methyl amentoflavone, bianthraquinone, podocarpusflavone A, and albanin F were shown to have the best affinity and inhibitory potential among the compounds, and can be explored clinically for use as inhibitors of novel coronavirus SARS-CoV-2.Communicated by Ramaswamy H. Sarma.

Multi-target direct-acting SARS-CoV-2 antivirals against the nucleotide-binding pockets of virus-specific proteins

The nucleotide-binding pockets (NBPs) in virus-specific proteins have proven to be the most successful antiviral targets for several viral diseases. Functionally important NBPs are found in various structural and non-structural proteins of SARS-CoV-2. In this study, the first successful multi-targeting attempt to identify effective antivirals has been made against NBPs in nsp12, nsp13, nsp14, nsp15, nsp16, and nucleocapsid (N) proteins of SARS-CoV-2. A structure-based drug repurposing in silico screening approach with ADME analysis identified small molecules targeting NBPs in SARS-CoV-2 proteins. Further, isothermal titration calorimetry (ITC) experiments validated the binding of top hit molecules to the purified N-protein. Importantly, cell-based antiviral assays revealed antiviral potency for INCB28060, darglitazone, and columbianadin with EC50 values 15.71 μM, 5.36 μM, and 22.52 μM, respectively. These effective antivirals targeting multiple proteins are envisioned to direct the development of antiviral therapy against SARS-CoV-2 and its emerging variants.

Occurrence of aflatoxin M1 in bovine milk and associated risk factors among dairy farms of Punjab, India

Aflatoxin M1 (AFM1) contamination in milk and milk products may pose a major public health concern. The present cross-sectional study was aimed to estimate the prevalence of AFM1 in bovine milk across all districts of Punjab, India and to identify the associated animal and farm level risk factors. A total of 402 milk samples (266 cow milk and 136 buffalo milk) were analysed using commercial ELISA and representative samples were confirmed using HPLC-FLD. The results revealed that 56.2 and 13.4% of the milk samples exceeded the maximum levels of the European Union, i.e. 0.05 μg/l and Food Safety and Standards Authority of India (FSSAI), i.e. 0.5 μg/l for AFM1 in milk, respectively. On analysis of species variation, buffalo milk (prevalence: 56.6%; mean concentration: 0.42±0.9 μg/l) was found to have higher AFM1 levels than cow milk (prevalence: 56.0%; mean concentration: 0.19±0.3 μg/l), with statistically significant difference between mean concentrations (P<0.01) and non-significant difference between AFM1 prevalence (P=0.91). Furthermore, milk from commercial dairy farms (prevalence: 64.7%; mean concentration: 0.34±0.65 μg/l) was found to be more contaminated than from household dairy establishments (prevalence: 47.8%; mean concentration: 0.19±0.65 μg/l). The risk factors ‘above average milk yield/day’ (odds ratio (OR): 2.4) and ‘poor animal hygiene’ (OR: 1.9) were identified at animal level, and ‘intensive dairy farming’ (OR: 3.1) and ‘animal feed without aflatoxin binder’ (OR: 4.7) as farm level risk factors for AFM1 excretion above maximum levels of European Union in milk. Among cow breeds, the milk from ‘non-descript’ breed (OR: 11.5) was found to be most contaminated with AFM1 and the least from Jersey breed (OR: 1.0). The present study highlighted the presence of AFM1 in milk samples; therefore, regular monitoring of AFM1 in milk is required so that high risk regions and associated risk factors can be addressed appropriately.